Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. - Wikidata - wikimedia - TriplyDB

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

http://www.wikidata.org/entity/Q34617300

about

Recent progress in pancreatic cancer Systemic Chemotherapy in Advanced Pancreatic Cancer Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Novel agents for advanced pancreatic cancer The Role of End-of-Life Issues in the Design and Reporting of Cancer Clinical Trials: A Structured Literature Review Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy Pancreatic cancer treatment and research: an international expert panel discussion.Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Advances in chemotherapy for pancreatic cancer Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine Immunohistochemical profile for unknown primary adenocarcinoma.A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.Intravenous ω-3 Fatty Acids Plus Gemcitabine.Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer.Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo Screening for pancreatic cancer: why, how, and who?Pancreatic adenocarcinoma Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials.

P2860

Q24626346-E561C2FC-2A23-410B-8B25-4F9D59D1E6BA Q26750440-C2344B33-16FA-46DD-A4AE-20960A0AD372 Q26767041-190412E5-D06C-4878-88A8-A60858CC3CA9 Q26787087-695C7CA6-568C-4FD8-9851-A1423EA17CD6 Q26795613-65EF23DD-7CBA-4545-8129-AD8682411133 Q26830913-CE432296-6203-4E54-A436-D98508635160 Q27008346-69498A9E-9703-4471-951E-B8026151F65F Q27690868-EE8452AE-482D-42E0-A380-36F29E554B6F Q28074614-D21BBFF5-EF8E-409F-8DDD-E087E7E4D4E7 Q28082919-EC071CC7-98F0-43BB-AC86-B0719F577E5F Q28085711-FA2299BF-7867-4FDE-AFC7-D8D07AE0152F Q29616728-6985ACF0-F104-4836-869F-FA563C7B823D Q31047832-D3646AE4-E423-41F7-8CAE-E9163CC36DE5 Q33394594-1224407A-009F-4096-8549-B504027E43E3 Q33395577-1EAC874D-9FEE-4296-92A8-C4D3E02254C4 Q33400095-887E0C18-0A92-4D1A-AD49-AEDCF27B97AB Q33401816-5C02126B-3268-4DD0-BB9D-2B669FDC09B2 Q33403498-7BA532BC-BE24-47FE-AC64-715F29C6EC80 Q33415850-40094C12-B65F-4FF0-8033-C5EEC2EDB1EE Q33417105-AFE4ABB6-492C-4855-A030-7372FB0FEBE7 Q33424793-0C114D49-CA20-4627-A7FD-8241CA84570F Q33427177-7765136F-39E8-4466-A72F-59BB21F095C3 Q33428016-F42BD100-678A-4C1B-8B0E-E7989D4B889D Q33429758-37D49A5A-F926-4590-989E-1229015F1F82 Q33430378-BDD5350F-1C36-46AA-897A-2FAC221B72D8 Q33440500-02C4F4E0-6B9A-4BD3-B0A6-D88F611B6F4A Q33442676-EF74E970-44AB-4248-931B-C193FB914EBB Q33615072-D0B6B4DF-A944-4D7D-9874-F40AFF7950EB Q33621256-6310887F-1E27-4430-AD36-09A0E7AA23AD Q33733758-013BD0F2-9905-493C-9DB6-861C9B840CCB Q33898080-A5BDA6F3-7176-4627-955A-D317FF685ABC Q33927370-3F4FA1D6-0DA6-463E-BF83-7C51DE10A659 Q33959412-AF280387-C917-4589-A4A2-13C24D1BF1D7 Q34140498-189C3963-66B8-41A2-9E6F-1EE8098D9E93 Q34177065-CCDCE57E-7D59-4598-9941-DA7F0762FE90 Q34294011-5FEEBEB3-B1E1-4416-9C3E-5604DF761F91 Q34301038-3CA8B38C-2A24-4B49-B578-AB2008D00B0A Q34308370-B293DA0C-5410-4FB4-BEDA-24B9389EB488 Q34326711-2A27E5A6-C2AA-4651-AB57-879F26D3FE1C Q34345296-9A9D49C2-DBA0-4281-A342-7A0520EE9AA7

P2860

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

http://www.wikidata.org/entity/Q34617300

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@ast

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@en

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@nl

type

label

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@ast

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@en

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@nl

prefLabel

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@ast

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@en

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@nl

P1433

Q34617300-63E44D7C-6E51-410B-8481-A88989FB6E1F

P1476

Q34617300-6DC99F09-34D6-4469-A3D2-DBC2648F7379

P2093

Q34617300-161F5BE0-A509-4441-A7F1-5CD417356017

Q34617300-1D2D193F-B049-474E-A178-56016A1D251A

Q34617300-2A20893D-C6C6-4540-B3CA-A65682519A09

Q34617300-403002F8-60B9-4753-9DFA-E527F81EC9BF

Q34617300-4340AE22-5DEB-492B-8A97-B778C58A4D7B

Q34617300-51FDECF2-7BAA-4D54-A396-6C2BE78A2FEA

Q34617300-68676A9C-F782-464C-B0CE-ACE083B7E80F

Q34617300-7C7BBB05-2886-4C42-8C5D-5E283515344E

Q34617300-7E7D0C5D-DDA9-425A-AE1C-0CE23FEAB166

Q34617300-A99190E0-065A-401C-AB4D-32D9DD58F4B9

P304

Q34617300-AA93E00A-D911-4D5C-9255-5315D3E8726B

P31

Q34617300-4484443A-B363-477D-BE8D-DB33F46A3C0D

P356

Q34617300-2298EF88-6CF2-4D8A-B44F-212224D230DB

P407

Q34617300-347DEDF0-648E-4991-9FF1-83DA154ED6AA

P433

Q34617300-2BB4B919-C86E-4ADB-A9FC-EF853E971073

P478

Q34617300-E6BDA3C6-70B7-4E3A-9674-AFA5265DC11E

P50

Q34617300-50E0CDF0-974A-4470-AB77-F6EC063C9E72

Q34617300-63CA7EFC-FF81-493B-A529-0483CF5B72E6

Q34617300-653374F3-70B2-4A76-9809-8607FEA8FA25

Q34617300-A62A8F64-376B-46ED-96A1-7A358DB2BF2B

Q34617300-B7745A28-4EB5-45D4-840E-2D9A841FAC06

Q34617300-DD60D937-BCB0-48D3-9EE3-0DDAE7F947FF

P577

Q34617300-5E82F362-7FDB-4A9C-92C1-84DDEB7711A1

P698

Q34617300-E7D6436F-9C18-425F-9879-F104236480AD

P921

Q34617300-12964F43-97D6-40AC-8ACC-C753D0611F70

Q34617300-5423FEAC-EC3B-41C0-9F66-07424B72F2EC

P356

JCO.2009.25.4433

P1433

Journal of Clinical Oncology

P1476

Randomized phase III trial of ...... eatic cancer: the GIP-1 study.

@en

P2093

Antonio Testa

http://www.w3.org/2001/XMLSchema#string

Bruno Massidda

http://www.w3.org/2001/XMLSchema#string

Ciro Gallo

http://www.w3.org/2001/XMLSchema#string

Elena Piazza

http://www.w3.org/2001/XMLSchema#string

Elisa Dapretto

http://www.w3.org/2001/XMLSchema#string

Francesco Di Costanzo

http://www.w3.org/2001/XMLSchema#string

Francesco Giuliani

http://www.w3.org/2001/XMLSchema#string

Francesco Perrone

http://www.w3.org/2001/XMLSchema#string

Giuseppe Colucci

http://www.w3.org/2001/XMLSchema#string

Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD)

http://www.w3.org/2001/XMLSchema#string

P304

1645-1651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.25.4433

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Falconi

Roberto Labianca

Giacomo Cartenì

Vittorio Gebbia

Massimo Di Maio

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20194854

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial